about
Cyanidin-3-glucoside suppresses cytokine-induced inflammatory response in human intestinal cells: comparison with 5-aminosalicylic acidSulphapyridine--a new agent for the treatment of ocular cicatricial pemphigoid.What should be considered on design of a colon-specific prodrug?Metabolic and pharmacological properties of rutin, a dietary quercetin glycoside, for treatment of inflammatory bowel disease.Synthesis and Characterization of 5-Aminosalicylic Acid Based Poly(anhydride-esters) by Solution Polymerization.Synthesis and properties of dextran-nalidixic acid ester as a colon-specific prodrug of nalidixic acid.Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation.Synthesis and in vitro properties of prednisolone 21-sulfate sodium as a colon-specific prodrug of prednisolone.Synthesis and properties of 5-aminosalicyl-taurine as a colon-specific prodrug of 5-aminosalicylic acid.Prednisolone 21-sulfate sodium: a colon-specific pro-drug of prednisolone.Susceptibility of glucocorticoids to colonic metabolism and pharmacologic intervention in the metabolism: implication for therapeutic activity of colon-specific glucocorticoid 21-sulfate sodium at the target site.A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis.Sulfate-conjugated methylprednisolone as a colon-targeted methylprednisolone prodrug with improved therapeutic properties against rat colitis.Dexamethasone 21-sulfate improves the therapeutic properties of dexamethasone against experimental rat colitis by specifically delivering the steroid to the large intestine.Mucosal interleukin-6 secretion in ulcerative colitis. Effects of anti-inflammatory drugs and T-cell stimulation.
P2860
Q28536900-4BE497FD-57E2-4DF9-8E31-7E0811F389C7Q37321480-FD2C7609-A72A-4A67-AE20-C10BCA41D11EQ37679957-8CF57EB6-6E6B-4018-8149-31A18B679A37Q40379789-4A8F1874-3801-4053-84EF-8FA6BA9C7E6FQ41866695-3AE96096-BA3F-43CC-B2A0-13E2D28DF4A1Q43644523-89D582BA-68A0-4279-91E2-A766067CF354Q44299613-42EE0FC1-F7D4-4826-812A-EC5FE2B0F417Q44432859-55E9DC65-DA2C-450C-A840-0EFD9B5E9C08Q44432862-488D0CD6-85BF-46AF-8A46-A96A50BA92F7Q44574216-BD9886C5-E4B1-4E36-ACF4-CBC14F9FA289Q45170592-13353F5D-9B04-4328-80A2-22ABC79532ADQ45243739-57C5AFF0-A187-461B-9911-283FB932300DQ45968857-125A42D0-A8E2-47ED-9A31-D97ADF1CE48BQ46287959-B7AD90B7-AE13-45B1-B49C-2265B10AF7F1Q52871467-F8FF90B9-6E79-42F6-946A-110F05451B12
P2860
description
1992 nî lūn-bûn
@nan
1992 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Drug therapy of ulcerative colitis
@ast
Drug therapy of ulcerative colitis
@en
Drug therapy of ulcerative colitis
@nl
type
label
Drug therapy of ulcerative colitis
@ast
Drug therapy of ulcerative colitis
@en
Drug therapy of ulcerative colitis
@nl
prefLabel
Drug therapy of ulcerative colitis
@ast
Drug therapy of ulcerative colitis
@en
Drug therapy of ulcerative colitis
@nl
P2860
P1476
Drug therapy of ulcerative colitis
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.1992.TB04124.X
P407
P577
1992-09-01T00:00:00Z